Results 51 to 60 of about 280,326 (218)
International Journal of Endocrinology, 2017 33 patients with active, moderate-severe Graves' ophthalmopathy (GO) received 4.5 g methylprednisolone for 12 weeks and were divided by efficacy into two groups (responsive and unresponsive). All patients and 10 controls underwent orbital MRI examination
Lingling Xu +4 more
semanticscholar +1 more source
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar +5 more
wiley +1 more source
Diagnostic accuracy of short-time inversion recovery sequence in Graves' ophthalmopathy before and after prednisone treatment [PDF]
, 2014 Introduction: In Graves' Ophthalmopathy, it is important to distinguish active inflammatory phase, responsive to immunosuppressive treatment, from fibrotic unresponsive inactive one.
Belfiore, M. P. +8 more
core +1 more source
Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease
Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset +13 more
wiley +1 more source
“Influence of Clinically Active Graves’ Ophthalmopathy on Spherical Equivalent and Visual Acuity”
Clinical Ophthalmology, 2022 Jasenka Petrovic Jurcevic,1 Marko Jurcevic,2 Mateja Jagic,3 Anamarija Jazbec,4 Kresimir Mandic,5 Jelena Juri Mandic5 1Medical School University of Zagreb, PhD Candidate on the Programme “Biomedicine and Health”, Zagreb, Croatia; 2University of Zagreb ...
Petrovic Jurcevic J +5 more
doaj
Journal of Ophthalmology, 2018 Objectives The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves' ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT).
Nan Yu +5 more
semanticscholar +1 more source
Miosite do músculo reto medial como forma atípica de apresentação de linfoma tipo MALT: relato de caso [PDF]
, 2014 Here we describe the rare case of a 55-year-old man with medial rectus muscle myositis as an atypical presentation of non-Hodgkin B-cell mucosa-associated lymphoma (MALT).
Dittrich, Mirtha Alicia Ramirez +4 more
core +4 more sources
Advanced Science, Volume 13, Issue 4, 19 January 2026.An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang +16 more
wiley +1 more source
A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody
Case Reports in Endocrinology, 2018 We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta +17 more
doaj +1 more source
Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development
Taiwan Journal of Ophthalmology, 2020 Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang +3 more
doaj +1 more source